Yuhan Replaces Merck To Market Samsung’s Biosimilars In Korea
Executive Summary
Local firm Yuhan is taking over from Merck as marketing partner in South Korea for Samsung Bioepis’ biosimilars amid speculation that weak sales of infliximab and etanercept may have triggered the realignment. Samsung Bioepis and Merck's broader partnership, however, remains intact.
You may also be interested in...
CHMP OKs First EU Biosimilar Herceptin, And Another Version Of Humira
Samsung Bioepis’s Ontruzant is set to be the first biosimilar version of Roche’s Herceptin on the EU market after getting the all-clear from the EMA’s CHMP on Sept. 15. The committee has also OKd another version of AbbVie’s Humira, this time from Boehringer Ingelheim.
Samsung Bioepis Builds Its Biosimilars Name In Europe
EU clearance of Samsung Bioepis' Imraldi, its adalimumab biosimilar, is the South Korean firm's third biosimilar anti-TNF alpha product to get approval in Europe.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.